<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The data of allogeneic HSCT in nine children with acquired AA between June 1998 and July 2006 were analyzed retrospectively </plain></SENT>
<SENT sid="1" pm="."><plain>The median duration of time to neutrophil and platelet engraftment was 18 and 25 days, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>None of the patients had primary graft failure </plain></SENT>
<SENT sid="3" pm="."><plain>Two (22.2%) patients developed <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD and of these, one (11.1%) was Grade 1, and the other (11.1%) was Grade 3 </plain></SENT>
<SENT sid="4" pm="."><plain>Although the study group was composed of higher risk patients, including six of nine resistant to previous immunosuppressive treatment, eight had multiple not irradiated or filtered transfusion histories and one of the cases was only 5/6 HLA-compatible with his donor, the five-yr overall and EFS was 100%, and <z:hpo ids='HP_0000001'>all</z:hpo> recipients are alive without any graft failure </plain></SENT>
<SENT sid="5" pm="."><plain>This may be attributed to the dose adjusted use of ATG according to individual transfusion history and gradual tapering of CsA and cessation at least nine months after allogeneic HSCT </plain></SENT>
</text></document>